Nile Therapeutics promotes Horton to president, CEO, director

Thursday, August 9, 2012 03:06 PM

Nile Therapeutics, a San Mateo, Calif.-based biopharmaceutical company that develops novel therapeutics for heart failure, has promoted Darlene Horton, M.D. to president, CEO and director of the company.

Horton served as Nile's CMO from June 2012 until her appointment as CEO. Previously, she served as CMO of Itero Biopharmaceuticals, a venture-backed biosimilar company. As a co-founder of Itero, she helped raise $17 million in capital and lead the development team. Previous to Itero, Horton served as senior vice president of clinical research at Scios, a Johnson & Johnson company. She also served as the head of the cardiovascular therapeutic area center of excellence for J&J pharmaceutical companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs